Ampio Pharmaceuticals, Inc. (AMPE): Price and Financial Metrics


Ampio Pharmaceuticals, Inc. (AMPE): $0.17

0.00 (2.83%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add AMPE to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

AMPE Stock Price Chart Interactive Chart >

Price chart for AMPE

AMPE Price/Volume Stats

Current price $0.17 52-week high $1.98
Prev. close $0.17 52-week low $0.15
Day low $0.16 Volume 4,394,900
Day high $0.17 Avg. volume 2,465,593
50-day MA $0.32 Dividend yield N/A
200-day MA $0.88 Market Cap 38.85M

Ampio Pharmaceuticals, Inc. (AMPE) Company Bio


Ampio Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of therapies for the treatment of prevalent inflammatory conditions in the United States. It is developing compounds that decrease inflammation by inhibiting specific pro-inflammatory compounds. The company's product pipeline includes Ampion, which is in phase III clinical trial, is an intra-articular injection for the treatment of osteoarthritis of the knee. Ampio Pharmaceuticals, Inc. has collaborative research agreements to explore new clinical indications for its immunomodulatory drug, Ampion. The company is headquartered in Englewood, Colorado.


AMPE Latest News Stream


Event/Time News Detail
Loading, please wait...

AMPE Latest Social Stream


Loading social stream, please wait...

View Full AMPE Social Stream

Latest AMPE News From Around the Web

Below are the latest news stories about Ampio Pharmaceuticals Inc that investors may wish to consider to help them evaluate AMPE as an investment opportunity.

Ampio Pharmaceuticals Presents Corporate Overview at H.C. Wainwright Bioconnect Conference

Ampio Pharmaceuticals, Inc. (NYSE: AMPE), a biopharmaceutical company focused on the advancement of immunology-based therapies for prevalent inflammatory conditions, today announced that it will present at the H.C. Wainwright Bioconnect Conference occurring virtually on January 10-13, 2022. Michael Martino, Chief Executive Officer, will present an updated corporate overview of Ampio and the presentation will be available on the event website beginning at 7:00 a.m. ET on January 10, 2022.

Yahoo | January 6, 2022

Ampio Pharmaceuticals (NYSEAMERICAN:AMPE) Cut to Hold at Zacks Investment Research

Zacks Investment Research lowered shares of Ampio Pharmaceuticals (NYSEAMERICAN:AMPE) from a buy rating to a hold rating in a report issued on Thursday morning, Zacks.com reports. According to Zacks, Ampio Pharmaceuticals, Inc. develops proprietary drugs for metabolic disease, eye disease, kidney disease, inflammation, CNS disease, and male sexual dysfunction. Principal products offered by the Company []

Dakota Financial News | December 19, 2021

Ampio Pharmaceuticals CEO Mike Martino Issues Letter to Stockholders

ENGLEWOOD, Colo., Dec. 16, 2021 Ampio Pharmaceuticals (NYSE American: AMPE), a biopharmaceutical company focused on the advancement of immunology-based therapies for prevalent Read More The post Ampio Pharmaceuticals CEO Mike Martino Issues Letter to Stockholders appeared first on Ampio Pharmaceuticals .

Ampio Pharmaceuticals | December 16, 2021

Ampio Pharmaceuticals' CEO Mike Martino Issues Letter to Stockholders

Ampio Pharmaceuticals (NYSE American: AMPE), a biopharmaceutical company focused on the advancement of immunology-based therapies for prevalent inflammatory conditions, today released the following letter to stockholders from its Chief Executive Officer, Mike Martino.

Yahoo | December 16, 2021

Ampio (AMPE) Upgraded to Buy: Here's What You Should Know

Ampio (AMPE) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Yahoo | December 14, 2021

Read More 'AMPE' Stories Here

AMPE Price Returns

1-mo -19.81%
3-mo -63.04%
6-mo -84.40%
1-year -90.61%
3-year -67.31%
5-year -77.63%
YTD -70.18%
2021 -64.15%
2020 172.73%
2019 47.59%
2018 -90.29%
2017 352.22%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.6655 seconds.